Correction to: Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention (High Blood Pressure & Cardiovascular Prevention, (2022), 29, 2, (91-102), 10.1007/s40292-021-00503-4)

In the online version of the article section 8 (Obesity), para 6, lines 1 to 5 which read as: Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, of the GLP1-RA semaglutide 3 mg administered weekly and the combination of naltrexone and bupropione. should read: Medications approved in Europe for weight loss in obese subjects currently include the lipase inhibitor orlistat at the dosage of 120 mg, the GLP1-RA liraglutide 3 mg administered daily or semaglutide 2.4 mg administered weekly and the combination of naltrexone and bupropione. In online version of the article Section 8 (Obesity), table (New recommendation), third point which reads as: Medications for weight loss in obese subjects, including orlistat, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient. should read: Medications for weight loss in obese subjects, including orlistat, liraglutide, semaglutide and the combination of naltrexone and bupropione may be considered when energy restriction and exercise are not sufficient. The original article has been corrected.